Maria Menounos Presents Keynote at 2020 ABTA National Conference
Maria Menounos, Emmy® Award-winning journalist, author and actress, joins the 2020 ABTA National Conference as Keynote Speaker to share her journey going from caregiver to brain tumor patient to survivor.
ABTA Announces Recipient of the Joel A. Gingras Award
We are pleased to announce Priscilla Brastianos, MD as the recipient of the ABTA Joel A. Gingras Award for her commitment to the ABTA’s mission through her groundbreaking work and leadership in brain metastasis research. Dr. Brastianos will be awarded the ABTA’s highest honor at the 2020 ABTA National Conference.
How Will You BT5K Your Way?
Whether you walk, bike, rollerblade or push a stroller, anyone, anywhere can BT5K Your Way. Get inspired by three participants joining our nationwide event in creative and unique ways that celebrate their family, friends and loved ones impacted by a brain tumor diagnosis.
Walking 1,000+ Miles for His Best Friend
This is Daniel and Craig. They became best friends in high school and remained steadfast buddies through the years. Neither distance
Accepting the Diagnosis and Defying the Prognosis
Kim and Jodi came together after their respective loved ones were impacted by a glioblastoma diagnosis. They found strength and healing
Liz’s Unexpected Brain Tumor Journey
This year, the BT5K Your Way run/walk event holds greater sentiment for Elizabeth and her mom, Heather. This past December, Elizabeth
STELLAR Study: Phase 3 Clinical Trial to Evaluate Eflornithine
**Sponsored Content**
If you or someone you know has been diagnosed with recurrent Anaplastic Astrocytoma, the STELLAR Study may be an option. It is a Phase 3 clinical trial currently enrolling in select sites across North America and Western Europe. To learn more please visit www.stellarstudy.com.
Upcoming Events
About Meet Hope Head On
Because of the generous support from people like you, the ABTA has given over $35 million for brain tumor research. The ABTA’s campaign, “Meet Hope Head On,” created for our 50th anniversary, is focused on raising $50 million, in part to fund critical brain tumor research. This campaign is vital for continuing the kind of work that led to the recent FDA approval of vorasidenib, a breakthrough treatment for low-grade glioma.
